



CUPID LIMITED

Manufacturer & Exporter of Male Condoms, Female Condoms,
Water based Lubricants & In Vitro Diagnostics (IVD) Kits

We Help The World Play Safe

Date: 28th January, 2026

To,

Department of Corporate Services,
BSE LIMITED,

Phiroze Jeejeebhoy Towers,
Dalal Street,

Mumbai – 400 001

SCRIP CODE: 530843

The National Stock Exchange of India Ltd.

Exchange Plaza, 5th Floor, Bandra-Kurla

Complex, Bandra (East),

Mumbai - 400051

Fax No. – 6641 8125 / 26

SCRIP CODE: CUPID

**Subject: - Press Release – Cupid Limited Receives CE (EU IVDR) Certification for HIV
1 & 2 and Hepatitis B IVD Test Kits, Expanding Global Market Access in Diagnostics**

Dear Sir / Madam,

With reference to the captioned subject, enclosed herewith the press release on Cupid Limited Receives CE (EU IVDR) Certification for HIV 1 & 2 and Hepatitis B IVD Test Kits, Expanding Global Market Access in Diagnostics.

The above is for your information and dissemination to the stakeholders.

Thanking you.

For Cupid Limited

Saurabh V. Karmase

Company Secretary and Compliance Officer

Factory & Registered Office:

CIN No.: L25193MH1993PLC070846



A-68, M.I.D.C. (Malegaon), Sinnar,
Nashik - 422113, Maharashtra, India



+91 2551 230280 / 230772
+91 7722009580



www.cupidlimited.com
info@cupidlimited.com



Cupid Limited Receives CE (EU IVDR) Certification for HIV 1&2 and Hepatitis B IVD Test Kits, Expanding Global Market Access in Diagnostics

Mumbai, 28th January, 2026: – Cupid Limited, (BSE – 530843, NSE – CUPID), a diversified Indian healthcare and consumer products company with a growing focus on in-vitro diagnostics (IVD), wellness, and personal care, announced that it has received **CE (EU IVDR) Certification for two in-vitro diagnostic (IVD) products – the CupiKIT HIV 1&2 Antibody Test Kit and the CupiKIT Hepatitis B Surface Antigen (HBsAg) Test Kit.**

The certifications have been granted under the **European Union In Vitro Diagnostic Regulation (EU) 2017/746 (IVDR), among the most stringent regulatory standards globally.** These approvals enable Cupid Limited to market the certified products across the European Economic Area (EEA) and other CE-recognized international markets.

The approvals mark a key milestone in Cupid's strategy to build a globally compliant and diversified rapid diagnostics portfolio. The addition of HIV 1&2 and Hepatitis B test kits strengthens the Company's footprint in infectious disease diagnostics, complementing its existing focus on maternal health and screening solutions.

The newly certified products are intended for early detection and large-scale screening programs, particularly across public health initiatives and institutional procurement channels in Europe, Africa, and other emerging markets. The certifications also enhance Cupid's eligibility to participate in government tenders, multilateral agency programs, and regulated international healthcare supply chains where EU IVDR compliance is mandatory.

These certifications further reinforce Cupid Limited's transition into a broader, innovation-led healthcare and diagnostics platform and position the Company to capitalize on rising global demand for accurate, affordable, and rapid diagnostic solutions.

Commenting on the development, Mr. Aditya Kumar Halwasiya, Chairman & Managing Director of Cupid Limited, said "The CE (EU IVDR) certification for our HIV 1&2 and Hepatitis B test kits is a meaningful step in strengthening our global diagnostics business. These approvals expand our access to regulated international markets and enhance our ability to participate in large-scale screening and public health programs. We continue to focus on building a reliable and affordable diagnostics portfolio while scaling our presence across key global regions to address growing healthcare needs."

About Cupid Limited

Established in 1993, Cupid Limited is a diversified Indian healthcare and consumer products company with a growing focus on in-vitro diagnostics (IVD), wellness, and personal care. Over the years, the Company has evolved from being a leading manufacturer of male and female condoms into a broader healthcare platform offering rapid diagnostic test kits, water-based personal lubricants, and a wide range of FMCG and wellness products.

Cupid has been actively expanding its diagnostics portfolio, particularly in rapid IVD test kits for infectious diseases and screening applications, aligned with global public health requirements. The Company operates with a strong commitment to quality, regulatory compliance, and ethical business practices, in line with international standards.

In line with its strategic growth plans, Cupid has also expanded into FMCG categories, including fragrance products (Eau de Parfums, deodorants, and pocket perfumes), personal care products such as toilet sanitizers, hair and body oils, hair removal sprays, face wash, petroleum jelly, and other wellness solutions.

In March 2024, the Company completed a strategic land acquisition in Palava, Maharashtra, to significantly expand its manufacturing capabilities. This expansion is expected to increase production capacity by 1.5 times, adding approximately 770 million male condoms and 75 million female condoms annually, while supporting future growth across healthcare and diagnostics segments.

Cupid Limited has a strong international footprint and is the first company globally to receive WHO/UNFPA pre-qualification for both male and female condoms. The Company exports to over 125 countries, with a substantial portion of revenue generated from international markets, and maintains a long-term supply relationship with WHO/UNFPA.

Cupid Limited is listed on the BSE (BSE: 530843) and the NSE (NSE: CUPID).

Disclaimer

Certain statements in this document that are not historical facts are forward looking statements. Such forward-looking statements are subject to certain risks and uncertainties like government actions, local, political or economic developments, technological risks, and many other factors that could cause actual results to differ materially from those contemplated by the relevant forward-looking statements. The Company will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.

For Further Information Please Contact Corporate Communication Advisor



Kirin Advisors Private Limited

Sunil Mudgal – Director

sunil@kirinadvisors.com

+91 98692 75849

www.kirinadvisors.com